Aduro BioTech Inc (NASDAQ:ADRO) CEO Stephen T. Isaacs sold 31,098 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $1.31, for a total transaction of $40,738.38. Following the completion of the transaction, the chief executive officer now directly owns 295,926 shares in the company, valued at approximately $387,663.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of NASDAQ:ADRO traded down $0.06 during trading hours on Tuesday, hitting $1.29. The stock had a trading volume of 190,300 shares, compared to its average volume of 519,906. The stock’s fifty day simple moving average is $1.31 and its 200 day simple moving average is $2.53. Aduro BioTech Inc has a 1-year low of $1.15 and a 1-year high of $7.64. The firm has a market capitalization of $106.59 million, a price-to-earnings ratio of -1.11 and a beta of 1.48. The company has a debt-to-equity ratio of 0.32, a quick ratio of 8.45 and a current ratio of 8.45.
Aduro BioTech (NASDAQ:ADRO) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.05). Aduro BioTech had a negative net margin of 624.51% and a negative return on equity of 68.69%. The firm had revenue of $4.89 million during the quarter, compared to analyst estimates of $4.56 million. As a group, research analysts anticipate that Aduro BioTech Inc will post -0.95 EPS for the current year.
A number of equities analysts have issued reports on ADRO shares. ValuEngine raised shares of Aduro BioTech from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Oppenheimer lowered shares of Aduro BioTech from an “outperform” rating to a “market perform” rating in a research note on Monday, June 3rd. Cowen restated a “buy” rating on shares of Aduro BioTech in a research note on Friday, August 2nd. Finally, CIBC restated a “market perform” rating on shares of Aduro BioTech in a research note on Monday, June 3rd. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $8.01.
About Aduro BioTech
Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.
Featured Article: Trading Options- What is a Strangle?
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.